Skip to main content
NVDA-0.40%AAPL-1.55%GOOGL+0.98%MSFT+2.21%AMZN+2.37%TSM-1.50%SPCX+0.36%META+0.24%AVGO+0.68%TSLA+2.05%SKHY+0.05%MU-0.46%BRK-B+0.79%LLY+0.50%AMD-1.57%JPM+0.45%WMT+0.46%V+2.44%XOM+0.22%ASMLa-1.84%JNJ+1.81%INTC-1.39%MA+1.94%0700.HK+3.26%ABBV+1.59%CSCO+2.60%1398.HK-0.92%CVX+0.38%COST-0.26%AMAT-0.09%AP2d-2.02%ORCL+4.43%LRCX0.00%DELL+1.07%BAC+0.92%KO+0.47%CAT+0.82%PG+0.44%UNH+2.02%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%HSBA.L+1.10%GE+0.33%PM-0.06%0857.HK0.00%0939.HK+0.83%NFLX-1.59%MS+1.13%1288.HK-1.52%NZDMXN+1.72%USDMXN+1.64%EURAUD-0.87%AUDJPY+0.65%AUDCHF+0.61%USDPLN+0.55%EURUSD-0.54%CHFSEK+0.49%EURZAR-0.48%AUDCAD+0.48%EURGBP-0.45%GBPAUD-0.45%AUDDKK+0.45%USDTRY+0.43%AUDNZD+0.43%EURNZD-0.43%GBPTRY+0.41%EURCAD-0.39%EURPLN+0.36%EURCHF-0.35%USDSEK+0.34%AUDUSD+0.33%AUDNOK+0.33%AUDSGD+0.33%EURCNH-0.32%GBPHKD+0.32%GBPZAR-0.30%USDZAR-0.30%PLNJPY-0.29%USDJPY+0.29%GBPMXN-0.28%EURJPY-0.28%CHFSGD+0.22%CHFNOK+0.21%USDCHF+0.20%SGDJPY+0.20%NOKJPY+0.19%EURHKD-0.18%GBPJPY+0.18%NZDJPY+0.18%USDDKK+0.18%USDILS+0.16%USDCAD+0.16%USDCNH-0.16%EURSEK+0.15%NZDSGD+0.14%EURNOK-0.12%EURSGD-0.12%CADJPY+0.12%GBPCHF+0.11%NZDUSD-0.10%NZDCHF+0.10%EURCZK+0.08%GBPUSD-0.08%CHFJPY+0.08%GBPCAD+0.08%USDSGD+0.06%USDNOK+0.06%NZDCAD+0.06%GBPSGD+0.06%USDCOP-0.04%CADCHF+0.04%GBPNZD+0.02%USDHKD+0.01%EURDKK-0.01%USDTHB0.00%C1-4.97%XNGUSD+3.00%GAGUSD+2.63%XAGUSD+2.63%XPTUSD+2.58%W1-2.40%HG1+2.24%GAUUSD+1.41%XAUUSD+1.41%S1-0.98%COTTON+0.62%USOIL+0.25%BTCUSD+1.10%ETHUSD+16.31%USDTUSD0.00%XRPUSD+8.70%SOLUSD+8.05%TRXUSDT+0.03%ZECUSDT+2.65%DOGEUSD+11.60%XMRUSDT-3.10%LINKUSD+12.58%XLMUSD+0.49%BCHUSDT+1.25%LTCUSD+5.93%UNIUSD+2.82%SUIUSD+2.02%HBARUSDT+0.08%TONUSD+24.22%TAOUSDT+2.37%AAVEUSD+1.81%DOTUSDT+10.20%ICPUSDT+4.23%ONDOUSDT+1.42%WLDUSDT+2.45%JUPUSDT+12.69%ARBUSDT+4.10%ATOMUSDT+14.34%STXUSDT-0.37%INJUSDT+2.66%FETUSDT+0.26%PYTHUSDT+0.07%SEIUSDT-0.89%TIAUSDT-5.89%IMXUSDT+0.33%GRTUSDT+3.28%OPUSDT+4.67%IOTAUSDT+0.62%WIFUSDT+1.64%AXSUSDT+1.42%POLUSDT+2.59%FARTCOINUSDT-1.04%EOSUSDT+4.63%DYDXUSDT+5.35%GALAUSDT+1.47%ORDIUSDT+0.51%RONINUSDT+2.73%NOTUSDT+3.72%NVDA-0.40%AAPL-1.55%GOOGL+0.98%MSFT+2.21%AMZN+2.37%TSM-1.50%SPCX+0.36%META+0.24%AVGO+0.68%TSLA+2.05%SKHY+0.05%MU-0.46%BRK-B+0.79%LLY+0.50%AMD-1.57%JPM+0.45%WMT+0.46%V+2.44%XOM+0.22%ASMLa-1.84%JNJ+1.81%INTC-1.39%MA+1.94%0700.HK+3.26%ABBV+1.59%CSCO+2.60%1398.HK-0.92%CVX+0.38%COST-0.26%AMAT-0.09%AP2d-2.02%ORCL+4.43%LRCX0.00%DELL+1.07%BAC+0.92%KO+0.47%CAT+0.82%PG+0.44%UNH+2.02%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%HSBA.L+1.10%GE+0.33%PM-0.06%0857.HK0.00%0939.HK+0.83%NFLX-1.59%MS+1.13%1288.HK-1.52%NZDMXN+1.72%USDMXN+1.64%EURAUD-0.87%AUDJPY+0.65%AUDCHF+0.61%USDPLN+0.55%EURUSD-0.54%CHFSEK+0.49%EURZAR-0.48%AUDCAD+0.48%EURGBP-0.45%GBPAUD-0.45%AUDDKK+0.45%USDTRY+0.43%AUDNZD+0.43%EURNZD-0.43%GBPTRY+0.41%EURCAD-0.39%EURPLN+0.36%EURCHF-0.35%USDSEK+0.34%AUDUSD+0.33%AUDNOK+0.33%AUDSGD+0.33%EURCNH-0.32%GBPHKD+0.32%GBPZAR-0.30%USDZAR-0.30%PLNJPY-0.29%USDJPY+0.29%GBPMXN-0.28%EURJPY-0.28%CHFSGD+0.22%CHFNOK+0.21%USDCHF+0.20%SGDJPY+0.20%NOKJPY+0.19%EURHKD-0.18%GBPJPY+0.18%NZDJPY+0.18%USDDKK+0.18%USDILS+0.16%USDCAD+0.16%USDCNH-0.16%EURSEK+0.15%NZDSGD+0.14%EURNOK-0.12%EURSGD-0.12%CADJPY+0.12%GBPCHF+0.11%NZDUSD-0.10%NZDCHF+0.10%EURCZK+0.08%GBPUSD-0.08%CHFJPY+0.08%GBPCAD+0.08%USDSGD+0.06%USDNOK+0.06%NZDCAD+0.06%GBPSGD+0.06%USDCOP-0.04%CADCHF+0.04%GBPNZD+0.02%USDHKD+0.01%EURDKK-0.01%USDTHB0.00%C1-4.97%XNGUSD+3.00%GAGUSD+2.63%XAGUSD+2.63%XPTUSD+2.58%W1-2.40%HG1+2.24%GAUUSD+1.41%XAUUSD+1.41%S1-0.98%COTTON+0.62%USOIL+0.25%BTCUSD+1.10%ETHUSD+16.31%USDTUSD0.00%XRPUSD+8.70%SOLUSD+8.05%TRXUSDT+0.03%ZECUSDT+2.65%DOGEUSD+11.60%XMRUSDT-3.10%LINKUSD+12.58%XLMUSD+0.49%BCHUSDT+1.25%LTCUSD+5.93%UNIUSD+2.82%SUIUSD+2.02%HBARUSDT+0.08%TONUSD+24.22%TAOUSDT+2.37%AAVEUSD+1.81%DOTUSDT+10.20%ICPUSDT+4.23%ONDOUSDT+1.42%WLDUSDT+2.45%JUPUSDT+12.69%ARBUSDT+4.10%ATOMUSDT+14.34%STXUSDT-0.37%INJUSDT+2.66%FETUSDT+0.26%PYTHUSDT+0.07%SEIUSDT-0.89%TIAUSDT-5.89%IMXUSDT+0.33%GRTUSDT+3.28%OPUSDT+4.67%IOTAUSDT+0.62%WIFUSDT+1.64%AXSUSDT+1.42%POLUSDT+2.59%FARTCOINUSDT-1.04%EOSUSDT+4.63%DYDXUSDT+5.35%GALAUSDT+1.47%ORDIUSDT+0.51%RONINUSDT+2.73%NOTUSDT+3.72%
AP

Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ • Healthcare

$224.53
+$0.12 (+0.1%)
Market open

Last close at October 8, 2026 at 20:00 UTC

Open$222.03
Previous Close$224.53
Day Range$218.39 - $225.9
Avg. Volume (3M)1.3M
Market Cap$30.9B
P/E Ratio36.8
52 Week Range
$197.81$495.55
Next EarningsIn 20 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1.2B100%
Gross Profitminus cost of goods$992.6M77%
Operating Incomeminus R&D and overhead$231.4M18%
Net Incomeminus taxes and the rest$164.4M13%

In plain terms: out of every $100 in revenue, Alnylam Pharmaceuticals, Inc. keeps $13 as net profit.

Fundamentals & Financials

Revenue (TTM)
$4.8B
Net Income (TTM)
$807.9M
EPS (TTM)
$6.1
ROA (TTM)
14.54%
Current Ratio
3.05

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-29.3%Q1 2026$0.82
+73.2%Q2 2026$1.51
-25.8%Q3 2026$1.21
Next

Oct 29

in 20 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -25.8%

Alnylam Pharmaceuticals trailed consensus on both EPS and revenue in the second fiscal quarter of 2026, reported July 30, even as revenue surged year over year. Revenue rose 66.9% to about $1.3 billion (up from roughly $773.7 million a year ago), but revenue of $1.291 billion trailed the $1.322 billion estimate (-2.4%). EPS of $1.21 trailed the $1.63 estimate (-25.8%), improving from -$0.51 a year ago, while net income turned positive to about $164.5 million versus a loss of roughly $66.3 million a year earlier. Profitability tracked with a gross margin near 77% and operating margin around 18%, alongside gross profit of about $992.7 million and operating income of roughly $231.4 million. The company generated operating cash flow of about $75.3 million. Next-period consensus calls for EPS of $2.19 on revenue of $1.429 billion.

Next report — what to expect

Alnylam Pharmaceuticals, Inc. (ALNY) reports next on October 29, 2026. The Street is looking for EPS of $1.77 on revenue of $1.43 billion. As trailing context, revenue rose +66.9% year over year last quarter. ALNY has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. develops RNA interference medicines in biotechnology and markets treatments for rare diseases, with $3.7 billion in revenue in FY2025. Listed on NASDAQ as ALNY, the company sells ONPATTRO for polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1.

Name
Alnylam Pharmaceuticals, Inc.
CEO
Yvonne L. Greenstreet
Website
www.alnylam.com
Industry
Healthcare
Year Founded
2002
Employees
2,500

Today's Snapshot

AI-generated

ALNY is trading 2.9% above yesterday's close, in line with a firmer sector.

Trading Volume

Below 10d avg (1.2M)

353.1K

vs S&P 500 Today

Outperforming Market

+2.36%

Updated: October 9, 2026 at 16:48 UTC

ALNY Headlines

ClearBridge Shifts Amid Growth Stock Turmoil

April 9, 2026

4 min read
View All News

Technical Indicators

0 Buy2 Neutral6 Sell
ALNY trades at 231.04 and is rated Strong Sell by technical measures, largely because momentum and MACD are decisively negative while price remains below most moving averages. Short‑ and medium‑term averages sit beneath the current level but the 100‑ and 200‑day averages remain well above, signaling longer‑term weakness; MACD is notably negative and momentum readings are bearish. ADX is modest, implying the downtrend lacks strong momentum, while ATR shows moderate volatility. Notably, on‑balance volume and pivot placement offer some limited support, but they do not offset the broader technical weakness. Technical takeaway: Strong Sell — negative momentum and moving‑average alignment dominate despite isolated support cues.
All signals
  • EMA (5 indicators)$231.54 - $306.41
    Sell
  • RSI (14)43.98
    Neutral
  • Stochastic %K (14, 3, 3)26.79
    Neutral
  • MACD Level (12, 26)-5.73
    Sell

Peers & Related Assets

ARWRArrowhead Pharmaceuticals, Inc.
$60.74-1.2%
IONSIonis Pharmaceuticals, Inc.
$43.3-1.9%
NTLAIntellia Therapeutics, Inc.
$12.6+7.6%
WVEWave Life Sciences Ltd.
$3.47-2.0%
SLNSilence Therapeutics plc
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.